Catalent (NYSE:CTLT) quickly rose 1% after a report that the contract drug manufacturer's $16.5 billion sale to Novo Holdings ...

Novo Holdings, the investment arm of the Novo Nordisk Foundation, has gained approval from the European Commission (EC) for ...

In the U.S., the chorus of opposition against the proposed buyout continues to grow and now includes the CEOs of Roche and ...

Novo Holdings’ $16.5 billion takeover of US contract development and manufacturing organisation (CDMO) Catalent does not ...

Novo Holdings on Friday gained unconditional EU antitrust approval for its $16.5 bln acquisition of U.S. contract drug maker ...

As the clock ticks down on 2024, Novo Holdings’ proposed $16.5 billion buyout of CDMO giant Catalent—which the companies have ...

Years of layoffs and alleged mismanagement have left employees “sick” of the pharmaceutical contract manufacturer Catalent, ...

The European Commission on Friday unconditionally approved a controversial deal in which Novo Holdings, the parent company of ...

The European Commission granted unconditional approval to Novo Holdings’ $16.5 billion takeover of Catalent, a decision both ...

Antag Therapeutics thinks its glucose dependent insulinotropic polypeptide receptor (GIPR) antagonist could carve out a space ...

Catalent, Inc. ("Catalent," NYSE: CTLT), a leader in enabling the development and supply of better treatments for patients worldwide, and Novo Holdings A/S ("Novo Holdings"), a global life sciences ...

Catalent (CTLT) and Novo Holdings announced that the European Commission has granted unconditional approval for the pending transaction under ...